Companies in #Glioblastoma Multiforme
Found 1 company operating in this sector.
Silexion Therapeutics is a clinical-stage biopharmaceutical company developing RNA interference (RNAi)-based cancer therapies and delivery systems for malignant solid tumors, built on its proprietary LODER delivery platform. Lead programs include SIL204, an RNAi therapeutic targeting KRAS-driven cancers now in clinical development, and SiG12D-LODER, which completed an open-label Phase 1 trial in pancreatic cancer; Prostate-LODER and GBM-LODER are in preclinical development. The company collaborates with Evonik on advanced siRNA formulation and is headquartered in Jerusalem, Israel, with a Nasdaq listing since 2025.